靶向特定T细胞亚群的inviKafusp alfa I/II期临床初步结果显示对免疫治疗耐药实体瘤具有疾病控制活性
A precision T-cell therapy stalls treatment-resistant cancers in clinical trial
发表于Nature Medicine的START-001 I/II期研究报道了inviKafusp alfa在人类中的早期结果。该药物由NIH、Mass General Brigham和Memorial Sloan Kettering的研究团队领导开展,旨在通过激活特定的肿瘤浸润淋巴细胞亚群来刺激抗肿瘤免疫,避免传统T细胞激活带来的严重副作用。
原文提供了I/II期试验在免疫治疗耐药实体瘤患者中的剂量与疾病控制数据,可用于理解该疗法的当前证据层级。
Early results of the first clinical trial to evaluate the drug invikafusp alfa (invika) in humans indicate that the treatment may be capable of managing cancers that have rebuffed most other interventions, including standard immunotherapy.
A study led by researchers at the National Institutes of Health (NIH), Mass General Brigham and Memorial Sloan Kettering found that, at optimal doses, invika was well tolerated and, in patients whose solid tumors had resisted standard immunotherapy, halted disease progression in most and shrank tumors in some. The work is published in the journal Nature Medicine.
"Patients whose tumors are advanced—particularly tumors that don't respond well to immunotherapy—often have their backs against a wall. Few options remain once you reach that point, but these results highlight a more precise means of stimulating antitumor immunity that could provide another solution," said co-corresponding author James Gulley, clinical director at the Center for Cancer Research (CCR), part of NIH's National Cancer Institute (NCI).
Targeting a narrow group of T cells
While immunotherapies have already transformed treatment for several cancers, many patients benefit from them for only a short time, or not at all. Tumors frequently adapt to immune checkpoint blockade (ICB) therapies, such as pembrolizumab, limiting long-term benefits. Other strategies aim to rally T cells, the frontline soldiers of adaptive immunity, but usually do so indiscriminately, commonly leading to severe side effects.
Scientists designed the protein invika to engage a small subset of T cells, two groups of tumor-infiltrating lymphocytes specifically. By activating only this narrow population rather than T cells broadly, invika is designed to drive antitumor activity while avoiding the severe side effects that less selective approaches can cause.
Preclinical studies also conducted at CCR indicate that the drug hits its intended marks and stimulates antitumor activity in animal models. This new study describes the next step for invika, detailing the results of phase 1 and initial phase 2 experiments in humans.
Tumor control at the optimal dose
The researchers leading the trial recruited patients with a wide variety of cancers, the majority of which had not responded well to ICB. In phase 1, they treated study participants with varying dosages of invika every two weeks to evaluate the drug's safety and determine the optimal dose. While several participants experienced flulike side effects, these were expected and generally manageable with additional medication and supportive care. After identifying the lowest dose at which desired effects peaked, the researchers advanced to phase 2, treating participants at this optimal dose.
Of the 27 participants treated with the optimal dose across both phases, disease did not progress in 16 (59.3%) of them. Four (14.8%) participants experienced greater than 30% decreases in the size of targeted tumors, two of whom had metastatic colorectal cancer with tumors of a notoriously treatment-resistant type and were receiving invika as their seventh-line therapy.
Another responsive participant had stage 4 non-small cell lung cancer, again with tumors that had repelled multiple therapies including ICB. In participants receiving nonoptimal levels, invika did not appear to have significant benefit.
Immune activity does not always predict benefit
In these patients, the study authors found that the drug fostered growth in the target T-cell populations without affecting any other T cells. They linked the four instances of tumor reduction to the largest shifts in target populations, though, as the authors expected at this early stage, immune activity alone did not always produce a measurable clinical response.
"These results are early, and although signs of immune activity don't always translate into benefit to patients at this stage, it is new and exciting to see activity in patients whose cancers had stopped responding to immunotherapy—a group of people with very few options left," said co-first author Nicholas Tschernia, a physician-scientist early investigator in the CCR at NCI.
"These findings give us a reason to keep studying this new type of immunotherapy, particularly by combining it with other cancer treatments to continue to seek improved results."
The treatment sponsor, Marengo Therapeutics, previously announced that the U.S. Food and Drug Administration (FDA) granted a fast-track designation to invika to accelerate its evaluation as a treatment for antigen-rich, metastatic colorectal cancer. More recently, FDA has granted the same designation to invika for similar solid tumors, regardless of tissue type, following prior therapy including checkpoint inhibitors.
Publication details
Ryan J. Sullivan et al., Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial, Nature Medicine (2026). DOI: 10.1038/s41591-026-04711-0
Journal information: Nature Medicine
Clinical categories
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: A precision T-cell therapy stalls treatment-resistant cancers in clinical trial (2026, October 23) retrieved 23 October 2026 from https://medicalxpress.com/news/2026-10-precision-cell-therapy-stalls-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com